Sumitomo Pharma
4506.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥249.5bn | ¥136.4bn | ¥98.2bn | ¥231.8bn | ¥302.4bn | ¥313.9bn |
| Operating income | ¥19.4bn | ¥11.6bn | −¥50.0bn | ¥54.9bn | ¥111.2bn | ¥127.7bn |
| Ordinary income | ¥62.9bn | ¥12.0bn | −¥6.5bn | ¥104.8bn | ¥140.9bn | ¥135.9bn |
| Total assets | ¥599.6bn | ¥523.4bn | ¥645.4bn | ¥1.09T | ¥1.19T | ¥1.17T |
| Net assets / equity | ¥273.8bn | ¥158.9bn | ¥108.4bn | ¥675.3bn | ¥850.4bn | ¥810.2bn |
| EPS (basic) | ¥289.41 | ¥267.28 | ¥-1,480.32 | ¥-460.52 | ¥147.81 | ¥293.23 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 190 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Asia | ¥23.0bn | ¥9.5bn |
| Japan | ¥92.4bn | ¥12.4bn |
| North America | ¥337.9bn | ¥75.7bn |
| Total | ¥453.3bn | ¥97.5bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.